Akoya Biosciences Q2 2024 GAAP EPS $(0.27), Inline, Sales $23.164M Miss $23.552M Estimate
Author: Benzinga Newsdesk | August 05, 2024 04:02pm
Akoya Biosciences (NASDAQ:
AKYA) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. The company reported quarterly sales of $23.164 million which missed the analyst consensus estimate of $23.552 million by 1.65 percent. This is a 1.52 percent decrease over sales of $23.521 million the same period last year.
Posted In: AKYA